Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | STING1 | Q86WV6 | 4/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HINT1 | P49773 | 1/20 | 0.46 |
| ▸ | TK1 | P04183 | 1/20 | 0.45 |
| ▸ | NT5E | P21589 | 1/20 | 0.44 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24264078 | 0.89 | ADORA3 (0.47) | ADORA3STING1PDE3BPDE3AHPGD | |
| SCHEMBL27040 | 0.85 | ADORA3 (0.54) | ADORA3STING1PDE3BPDE3AHPGD | |
| SCHEMBL3033632 | 0.85 | ADORA3 (0.54) | ADORA3STING1PDE3BPDE3AHPGD | |
| SCHEMBL24703672 | 0.85 | ADORA3 (0.54) | ADORA3STING1PDE3BPDE3AHPGD | |
| SCHEMBL14946338 | 0.85 | ADORA3 (0.54) | ADORA3STING1PDE3BPDE3AHPGD | |
| SCHEMBL14929377 | 0.85 | ADORA3 (0.54) | ADORA3STING1PDE3BPDE3AHPGD | |
| SCHEMBL19820350 | 0.85 | ADORA3 (0.54) | ADORA3STING1PDE3BPDE3AHPGD | |
| SCHEMBL10188878 | 0.85 | TAS1R3 (0.52) | ADORA3HPGDTK1 | |
| SCHEMBL15478054 | 0.85 | TAS1R3 (0.52) | ADORA3HPGDTK1 | |
| SCHEMBL803398 | 0.85 | TAS1R3 (0.52) | ADORA3HPGDTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220056451-A1 | HBV BINDING OLIGONUCLEOTIDES AND METHODS OF USE | ALIGOS THERAPEUTICS, INC. | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220056451-A1 | HBV BINDING OLIGONUCLEOTIDES AND METHODS OF USE | HAVCR2, POLRMT, DCLRE1B | ADORA3 1448/4885STING1 136/4885PDE3B 4541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.